Search tips
Search criteria 


Logo of jcinvestThe Journal of Clinical Investigation
J Clin Invest. 1999 June 15; 103(12): 1729–1735.
PMCID: PMC408392

Mitogen-activated protein kinase inhibits 1,25-dihydroxyvitamin D3–dependent signal transduction by phosphorylating human retinoid X receptor α


Human retinoid X receptor α (hRXRα) is a member of the nuclear receptor family of transcriptional regulators. It regulates transcription through its association with several heterodimeric partners, including the vitamin D3 receptor (VDR). Signaling through the VDR is essential for normal calcium homeostasis and has been shown to inhibit the proliferation of cancer cells derived from a number of tissues. Here we show that phosphorylation of hRXRα in ras-transformed human keratinocytes through the activated Ras–Raf–mitogen-activated protein kinase (Ras-Raf-MAP kinase) pathway results in attenuated transactivation by the VDR and resistance to the growth inhibitory action of 1,25 dihydroxyvitamin D3 [1,25(OH)2D3] and RXR-specific agonist LG1069 (4-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphtalenyl) ethenyl]-benzoic acid). Phosphorylation of hRXRα occurs at serine 260, a consensus MAP kinase site. Inhibition of MAP kinase activity or point mutagenesis of serine 260 of hRXRα reverses the observed resistance to 1,25(OH)2D3 and LG1069. Thus, hRXRα is a downstream target of MAP kinase, and its phosphorylation may play an important role in malignant transformation.

J. Clin. Invest. 103:1729–1735 (1999).


Resistance to anti-tumor agents is often a limiting factor in cancer therapy (1). Activation of ras, the most common oncogene implicated in human cancer, has been detected in a wide variety of tumors, including carcinomas of the pancreas and squamous tumors of the colon, lung, skin, and breast (2). Activation of the Ras–Raf–mitogen-activated protein kinase (Ras-Raf-MAP kinase) pathway leads to phosphorylation of numerous downstream targets (3) and is a potential mechanism for the control of nuclear receptor activation and function (4).

The biologically active form of vitamin D3, 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], directly modulates the transcription of several target genes by binding to the vitamin D3 receptor (VDR), a member of the nuclear receptor family of transcriptional regulators. The ligand-bound VDR functions as a heterodimer by interacting with members of the retinoid X receptor (RXR) family of nuclear receptors (5). An extensive body of literature links the function of 1,25(OH)2D3 to the inhibition of cancer cell growth and stimulation of cellular differentiation. Administration of 1,25(OH)2D3 prolonged the life expectancy of leukemic mice (6), inhibited the formation of preneoplastic mammary lesions in rats, and inhibited the proliferation of cancer cell lines derived from many tissues, including breast (7), endometrium (8), head and neck (9), lung (10), prostate (11), and hematopoietic lineages (12). However, several cancer cell lines have been identified as resistant to the growth inhibitory action of 1,25(OH)2D3, including squamous cell carcinomas derived from human keratinocytes (13), human pancreatic cancer cells (14), and human breast carcinoma cells (15). An understanding of tumor cells’ mechanism of resistance to 1,25(OH)2D3 could lead to new methods for controlling the deregulated growth of these cells.

The transformed human keratinocyte cell line HPK1Aras overexpresses H-ras and forms squamous tumors in nude mice (16). Unlike the parental HPK1A cell line and normal human keratinocytes, HPK1Aras cells are partially resistant to growth inhibition by 1,25(OH)2D3 (13). Human retinoid X receptor α (hRXRα) is the predominant RXR expressed in these cells (17). Interestingly, VDR/RXR complexes formed on vitamin D response element (VDRE) oligonucleotides can be supershifted with an antibody that recognizes the hRXRα ligand-binding domain (LBD) in extracts of normal human keratinocytes and HPK1A cells but not ras-transformed HPK1Aras cells (17). The LBD of hRXRα possesses an interface for interaction with heterodimerization partners such as the VDR, thyroid hormone receptors (TRs), and retinoic acid receptors (RARs) (18). Here we show that the LBD of hRXRα is a nuclear target of MAP kinase in HPK1Aras cells, which affects its normal function through phosphorylation at a specific site.


Cell growth assays and transfections.

The HPK1A and HPK1Aras cell lines have been described (16, 13, 19). HPK1A cells are nontumorigenic, whereas HPK1Aras cells form colonies in soft agar and produce invasive squamous cell carcinomas when transplanted into nude mice. For assessment of cell growth, HPK1A and HPK1Aras cells were seeded in 24-well plates at a density of 4 × 103 cells per well and grown in DMEM (GIBCO BRL, Burlington, Ontario, Canada) supplemented with 10% FBS. When the cells reached 40% confluence, the medium was replaced with serum-free DMEM for 24 hours to synchronize the cells. At time 0, the medium was replaced with DMEM supplemented with 5% charcoal-stripped FBS in the presence of increasing concentrations of 1,25(OH)2D3 (10–10 to 10–7 M) or LG1069 (10–10 to 10–6 M) (a kind gift of E. Allegretto, Ligand Pharmaceuticals, San Diego, California, USA). In some experiments, cells were treated with 25 μM of the mitogen-activated protein kinase kinase (MAPKK) inhibitor PD098059 (Research Biochemical International, Natick, Massachusetts, USA). Cells were trypsinized after 96 hours and counted with a Coulter counter (Coulter Electronics, Lufton, United Kingdom). Cell activity was also assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) formazan assay. Briefly, this procedure assesses cellular growth based on the intensity of a colorimetric reaction resulting from the reduction of a tetrazolium reagent (Promega Corp., Madison, Wisconsin, USA) to a soluble formazan salt, with absorbance being directly proportional to viable cell density. Cells were seeded with 2 × 103 cells per well in 96-well plates and treated with LG1069 as above. This assay was performed as described previously (13). For the transfection studies, cells were grown in 6-well plates seeded with 4 × 105 cells per well. At 60% confluence, cells were transfected with 5 μg of the 1,25(OH)2D3-sensitive chloramphenicol acetyl transferase (CAT) reporter plasmid mOP3 (20) and 0.1 μg of a human growth hormone (hGH) reporter plasmid (22) as an internal control for transfection efficiency (17). Transfections were performed by incubating plasmid DNA (5 μg) with Lipofectamine (GIBCO BRL) (15 μg) for 20 hours in Opti-MEM (GIBCO BRL) and then replacing the medium with fresh DMEM containing 10% FBS with varying concentrations of 1,25(OH)2D3 or LG1069 in the absence or presence of 25 μM PD098059 for 24 hours. The medium was retained for the hGH assay. The cells were trypsinized, washed in PBS, resuspended in 0.25 M Tris-HCl (pH 8.0), and lysed by 5 freeze-thaw cycles. The cell lysate was centrifuged, and aliquots of cell extracts were used for the CAT assays. Assays were performed using a CAT ELISA kit (5 Prime-3 Prime, Boulder, Colorado, USA). Human growth hormone assays were performed using an hGH ELISA kit (Boehringer Mannheim, Laval, Quebec, Canada).

Nuclear extracts.

Nuclear extracts were prepared from HPK1A and HPK1Aras cells as described previously (17). Nuclear extracts were also prepared from HPK1A and HPK1Aras cells that had been treated with 25 μM PD098059 for 48 hours prior to extraction.

Gel mobility shift analysis.

Nuclear extracts (2 μg) were incubated for 20 minutes on ice with 10–7 M 1,25(OH)2D3 and 1 μg poly dI.dC in a binding buffer (25 mM Tris-HCl [pH 8.0], 5% glycerol, 0.5 mM DTT). Five femtomoles of the 32P-labeled mouse osteopontin VDRE (mOP VDRE) (5′-GTACAAGGTTCACGAGGTTCACGTCTTA-3′) was added and incubated for 20 minutes at room temperature. When required, specific antibodies were added to the incubation. The anti-RXR antibody 4X1D12 recognizes the COOH-terminal domain of RXR and produces a supershift (a kind gift of P. Chambon, College de France, Illkirch, France). The anti-VDR antibody recognizes the LBD of VDR and produces a supershift (Affinity BioReagents Inc., Neshanic Station, New Jersey, USA). The anti-RXR antibody that recognizes the NH2-terminal domain of RXR close to the DNA-binding domain inhibits formation of the complex (Santa Cruz Biotechnology Inc., Santa Cruz, California, USA) (23). The samples were electrophoresed on 5% nondenaturing polyacrylamide gels, dried, and exposed to Kodak XAR-5 film.


Serine and threonine phosphorylation of hRXRα from HPK1A and HPK1Aras cells was determined by immunoprecipitating hRXRα from 100 μg of total protein from the nuclear extracts through a 2-hour incubation at 4°C with 1 μg of a polyclonal anti-RXRα antibody that recognizes the LBD of hRXRα (Santa Cruz Biotechnology Inc.) or an anti-hemagglutinin (HA) antibody (Babco, Berkeley, CA). Protein content was determined with a protein assay kit (Bio-Rad Laboratories, Mississauga, Ontario, Canada). The mixture was incubated overnight with protein G-Sepharose beads (Pharmacia Biotech, Baie d’Urfé, Quebec, Canada). Immunoprecipitates were washed 4 times in radioimmunoprecipitation assay (RIPA) buffer (0.1% SDS, 1% NP-40, 0.5% sodium deoxycholate, 150 mM NaCl, 50 mM Tris-HCl [pH 7.4], 1 mM EDTA, 0.25 mM phenylmethylsulfonylfluoride), boiled for 5 minutes, resolved on 10% SDS-PAGE, and transferred to PVDF membranes (Bio-Rad Laboratories Inc., Hercules, California, USA). Blots were probed with monoclonal anti-phosphoserine or anti-phosphothreonine antibodies (diluted to 1:3,000) (Sigma Chemical Co., St. Louis, Missouri, USA). After incubation with a horseradish peroxidase–conjugated secondary antibody (Bio-Rad Laboratories), the complexes were viewed by enhanced chemiluminescence (ECL; Amersham Life Sciences Inc., Arlington Heights, Illinois, USA).

Site-directed mutagenesis.

The ala260 hRXRα mutant was constructed through a double PCR (24) using an hRXRα expression plasmid (a kind gift of R. Evans, The Salk Institute of Biological Sciences, La Jolla, California, USA) (17) and was subcloned into the EcoRI site of pGEM-7Zf(+) (Promega Corp.). The external oligonucleotides used were: downstream, hRXRα (5′-CTCCAAGGACGCATAGAC-3′), and upstream, hRXRα (5′-GGAACGAGAATGAGGTGG-3′), encompassing the BssHII and SalI sites. Internal oligonucleotides were as follows (with the alanine mutations underlined): upstream, 5′-GAACCCCGCCGCGCCGAACGACCCTGTCACCAACATTTGC-3′; and downstream, 5′-TTCGGCGCGGCGGGGTTCAGCCCCATGTTTG-3′. The BssHII-SalI fragment was then ligated into the hRXRα plasmid, and the mutant hRXRα was subcloned into the plasmid pcDNA3HA (a kind gift of H. Imataka, McGill University, Montreal, Quebec, Canada), which contains a synthetic oligonucleotide encoding the HA epitope inserted into the HindIII site of pcDNA3 (Invitrogen Corp., Carlsbad, California, USA). Sequence of the ala260 hRXRα mutant was verified by chain-termination sequencing.

In vitro kinase assay.

COS-7 cells were grown in DMEM supplemented with 10% FBS. Transfections were performed by incubating 5 μg of plasmid DNA expressing the human vitamin D receptor (hVDR) (a kind gift of M. Haussler, University of Arizona, Tucson, Arizona, USA) and 5 μg of plasmid DNA encoding either wild-type hRXRα or the ala260 hRXRα mutant with 15 μg Lipofectamine, as described above. Transiently transfected cells were harvested for gel retardation assays 48 hours after transfection by washing the cells twice in PBS and then collecting them in 1 mL PBS. Cells were centrifuged at 500 g for 10 minutes at 4°C, and the pellets were resuspended in 1 mL of high-salt buffer (25 mM Tris [pH 7.5], 0.3 mM DTT, 0.1 M KCl, 20% glycerol). Cells were lysed by 3 freeze-thaw cycles and then centrifuged at 10,000 g for 15 minutes at 4°C. Cell extract (2 μg) was incubated in 1× MAP kinase buffer (New England Biolabs Inc., Beverly, Massachusetts, USA), 5 mM ATP, and activated recombinant MAP kinase (Calbiochem-Novabiochem Corp., Hornby, Ontario, Canada) at 30°C for 15 minutes. MAP kinase–treated cell extracts were then subjected to gel mobility shift analysis as described above.

Statistical analysis.

Statistical significance was determined by one-way ANOVA or by Student’s t test. A probability value of P < 0.05 was considered to be significant.


Inhibition of MAP kinase activity reverses the phenotypic resistance of ras-transformed keratinocytes to 1,25(OH)2D3.

The role of MAP kinase activation in partial resistance of HPK1Aras cells to growth inhibition by 1,25(OH)2D3 was first analyzed using PD098059, which is a selective inhibitor of MAPKK, the enzyme directly responsible for the activation of MAP kinase (21). The effect of PD098059 on 1,25(OH)2D3-dependent transactivation was assessed by transfecting HPK1Aras cells with the 1,25(OH)2D3-sensitive CAT reporter plasmid mOP3 (20). PD098059 treatment of HPK1Aras cells completely reversed partial resistance to 1,25(OH)2D3-dependent transactivation (Figure (Figure1a).1a). Treatment with PD098059 also reversed partial 1,25(OH)2D3 resistance of HPK1Aras cells observed in growth curves (Figure (Figure1b),1b), as well as in thymidine incorporation and formazan assays (data not shown).

Figure 1
Effect of 1,25(OH)2D3 and PD098059 on cell growth in HPK1A and HPK1Aras cells. Cells were transfected with the mOP3 reporter plasmid (20) and the growth hormone expression plasmid pLTR-GH, and then were treated with increasing concentrations of 1,25(OH) ...

Human RXRα is phosphorylated on serine 260 in ras-transformed keratinocytes.

Complexes of identical mobility containing the VDR were formed in electrophoretic mobility shift assays (EMSAs) using a mOP VDRE oligonucleotide and extracts of HPK1A and HPK1Aras cells (Figure (Figure2a).2a). The supershifting VDR antibody (Figure (Figure2a,2a, lanes 3, 6, 9, and 12) did not shift the entire complex, suggesting the presence of other heterodimers containing RXR at this site. However, a different monoclonal VDR antibody that inhibits formation of a VDR/RXR complex on the mOP VDRE has been used previously (17) and is able to inhibit formation of this complex in its entirety, indicating that this complex contains only heterodimers of VDR/RXR. However, unlike the complexes formed in extracts of HPK1A cells (Figure (Figure2a,2a, lanes 4 and 7), those formed in ras-transformed cells could be shifted with an antibody recognizing the LBD of hRXRα only if the cells were pretreated with PD098059 (Figure (Figure2a,2a, lane 13). Identical results were obtained in EMSAs performed using a human osteocalcin VDRE (data not shown). Furthermore, experiments performed using a different antibody recognizing the NH2-terminal domain of hRXRα inhibited complex formation in both HPK1A and HPK1Aras cell extracts, revealing that hRXRα was indeed present in these heterodimers (Figure (Figure2b).2b). These results raised the possibility that hRXRα in HPK1Aras cells was phosphorylated by the activated MAP kinase pathway. Western analysis of extracts immunoprecipitated with an antibody recognizing the NH2-terminus of hRXRα showed that similar levels of hRXRα protein were expressed in HPK1A and HPK1Aras cells (Figure (Figure2c,2c, top). Unlike the VDR, which contains no MAP kinase consensus sequences, hRXRα contains 2 MAP kinase sites, one at threonine 82 and another at serine 260 (ser260). Human RXRα was phosphorylated to similar degrees on threonine residues in HPK1A and HPK1Aras cells (Figure (Figure2c,2c, middle). In contrast, phosphorylation on serine residues was observed only in HPK1Aras cells. Threonine phosphorylation was not affected by treatment of cells with PD098059, whereas serine phosphorylation in HPK1Aras cells was completely eliminated (Figure (Figure2c,2c, lane 4, middle and bottom). Western analysis with anti-phosphoserine and anti-phosphothreonine antibodies did not detect any differences in VDR phosphorylation in HPK1A and HPK1Aras cells (data not shown).

Figure 2
Effect of 1,25(OH)2D3 and PD098059 on VDR/RXR complex formation in HPK1A and HPK1Aras cells. (a) A mOP VDRE was 32P labeled and incubated with nuclear extracts from HPK1A cells (lanes 2–4), PD098059-treated HPK1A cells (lanes 5–7), HPK1A ...

Further evidence for the role of MAP kinase–dependent phosphorylation of hRXRα in modulating 1,25(OH)2D3-dependent transactivation came from experiments in HPK1A cells transiently transfected with a constitutively active MAPKK expression vector (Figure (Figure3a).3a). VDR-dependent transactivation was observed only at high concentrations of 1,25(OH)2D3 in HPK1A cells transfected with constitutively active MAPKK, whereas transactivation in cells transfected with an inactive MAPKK control was unaffected. Moreover, expression of constitutively active MAPKK in HPK1A cells induced phosphorylation on serine of hRXRα (Figure (Figure3b,3b, lane 2, top).

Figure 3
MAP kinase–dependent phosphorylation of hRXRα in HPK1A and HPK1Aras cells. (a) HPK1A cells were transfected with activated or inactivated MAPKK expression plasmids and were treated with increasing concentrations of 1,25(OH)2D3 and 5% ...

Mutation of ser260 of hRXRα abolishes partial resistance to 1,25(OH)2D3 in ras-transformed keratinocytes.

A mutant hRXRα was constructed with the putative phosphorylation site, ser260, mutated to an alanine (ala260). Gene transfer experiments were performed in which HPK1Aras cells were transfected with vectors expressing either the wild-type or the ala260 mutant hRXRα. Whereas HPK1Aras cells overexpressing the wild-type hRXRα remained resistant to 1,25(OH)2D3, this resistance was abolished in HPK1Aras cells overexpressing the mutant construct (Figure (Figure4a).4a). The mutant was tagged by cloning it into a plasmid, pcDNA3HA, which possesses a synthetic oligonucleotide that encodes the HA epitope tag. Nuclear extracts were prepared from the HPK1Aras cells expressing the tagged mutant and immunoprecipitated with an antibody to the HA epitope. Blots probed with anti-phosphoserine antibody revealed that the mutant hRXRα protein was not phosphorylated on serine, unlike wild-type hRXRα (Figure (Figure4b),4b), and firmly established that ser260 was the target site of MAP kinase in the hRXRα.

Figure 4
Mutation of hRXRα at ser260 abrogates MAP kinase–dependent phosphorylation and eliminates partial resistance to 1,25(OH)2D3. (a) HPK1Aras cells were transfected with vectors expressing either wild-type hRXRα or hRXRα containing ...

In vitro phosphorylation of hRXRα by MAP kinase prevents the supershift of the VDR/RXR complex on gel retardation assays.

An in vitro kinase assay was performed and revealed that extracts of COS-7 cells transiently transfected with wild-type hRXRα and treated with recombinant MAP kinase formed complexes on a VDRE that could not be supershifted with the anti-RXR antibody (Figure (Figure4c,4c, lane 3). Furthermore, extracts of COS-7 cells transfected with the ala260 hRXRα mutant and treated with recombinant MAP kinase formed complexes in gel retardation assays that could be shifted in the presence of the anti-RXR antibody (Figure (Figure4c,4c, lane 7). This result firmly established that phosphorylation of hRXRα at ser260 by MAP kinase renders the VDR/RXR complex unshiftable by the anti-RXR antibody on gel retardation assays.

Ras-transformed keratinocytes also exhibit a resistance to the RXR-specific ligand LG1069.

LG1069 specifically binds RXR and promotes RXR/RXR homodimers. This ligand was used to determine if the phosphorylation event observed in ras-transformed keratinocytes affected other signaling pathways involving RXR, in addition to vitamin D signaling. Growth of the HPK1A cells, as determined by cell count or formazan assay, was inhibited by LG1069, whereas the HPK1Aras cells were completely resistant to the growth inhibitory action of LG1069 (Figure (Figure5,5, a and b). This resistance phenomenon of the ras-transformed cells to LG1069 was completely reversed following treatment with the MAPKK inhibitor PD098059. Hence, phosphorylation of hRXRα by MAP kinase does influence signal transduction pathways in the ras-transformed keratinocytes involving nuclear receptors other than the VDR.

Figure 5
Effect of an RXR-specific ligand, LG1069, on HPK1A and HPK1Aras cells. (a) Cells were treated with increasing concentrations of LG1069 (10–10 to 10–6 M) in the absence or presence of 25 μM PD098059 and 5% charcoal-stripped ...


Several cell lines derived from in vivo tumors have demonstrated resistance to the growth inhibitory influences of 1,25(OH)2D3 (1315, 17). It is not uncommon to observe the spontaneous development of resistance to a growth inhibitory substance in human cancer. The occurrence of 1,25(OH)2D3 resistance reported in this study is not associated with a genetic alteration of the VDR (17). In addition, Western analyses showed that hRXRα is expressed at similar levels in HPK1A and HPK1Aras cells, suggesting that partial resistance to 1,25(OH)2D3 in HPK1Aras cells does not arise from increased degradation of hRXRα. Instead, this study indicates that transcriptional activation by the VDR is attenuated through phosphorylation of the heterodimeric partner hRXRα by MAP kinase. This posttranslational modification is mediated through overexpression of the ras oncoprotein, which induces the Ras-Raf-MAP kinase cascade in HPK1Aras cells and stimulates phosphorylation of hRXRα on ser260.

The resistance phenomenon observed in HPK1Aras cells not only affects cell growth, but also affects endogenous genes known to be important in the control of cell growth and differentiation (13, 25). In particular, the observed resistance to parathyroid hormone–related peptide (PTHrP) expression by HPK1Aras cells detected previously (25) is especially relevant because PTHrP was found to be antiproliferative (26) and prodifferentiative (26) in HPK1A cells.

Although our present study defines a specific cellular model, the potential ramifications of these findings are extensive. 1,25(OH)2D3 inhibits the growth of tumors derived from a variety of tissues (27). Given the high frequency of ras activation in human cancers, phosphorylation of hRXRα may be a common mechanism by which cancer cells escape the growth inhibitory effects of the endogenously produced hormone 1,25(OH)2D3. Moreover, hRXRα functions in a wide variety of transcriptional responses through its heterodimerization with several nuclear receptors in addition to the VDR, including thyroid hormone receptors (TRs), retinoic acid receptors (RARs), peroxisome proliferator–activated receptors (PPARs), and several orphan receptors (18). Signaling through heterodimeric partners of RXRs other than the VDR can modulate cellular growth and differentiation. For example, PPARα promotes differentiation of adipocytes (28) and has recently been shown to inhibit growth of colon cancer cell lines (29). Consequently, disruption of signal transduction by members of this superfamily of receptors could have multiple consequences for the control of cell growth and differentiation.

Through studies with the RXR-specific ligand LG1069, we have demonstrated that this MAP kinase phosphorylation of hRXRα in ras-transformed keratinocytes affects another signaling pathway that relies on the RXR. The ras-transformed cells are not only resistant to the growth inhibitory action of 1,25(OH)2D3 but are also resistant to the growth inhibitory action of LG1069. Furthermore, we have shown previously in gel retardation assays a similar phenomenon in thyroid hormone signaling; the RXR antibody also fails to shift TR/hRXRα heterodimers formed on thyroid hormone response elements (TREs) (17).

Targeting hRXRα confers a growth advantage to cells that have been transformed by ras by affecting several signaling pathways that depend on RXR. Because 1,25(OH)2D3 is a powerful inhibitor of cell growth, it is beneficial for a cancer cell to resist this inhibitory pathway. In addition, by affecting the common link among many nuclear receptor pathways, cells transformed by ras are able to influence signal transduction in a much broader sense. Although this study focused on 1,25(OH)2D3 action, we have demonstrated that phosphorylation of hRXRα on ser260 also affects RXR/RXR signaling, indicating that this is a common mechanism used by ras-transformed keratinocytes to interfere with hormone signaling.

Gel retardation assays performed in the presence of specific antibodies raise the possibility that phosphorylation of hRXRα on ser260 induces a conformational change within the receptor that causes attenuation of ligand-dependent transactivation. An anti-RXR antibody with an epitope spanning ser260 was unable to recognize and therefore supershift the VDR/RXR complex from the ras-transformed keratinocytes (Figure (Figure2a),2a), whereas an anti-RXR antibody possessing an epitope in the NH2-terminal domain of hRXRα remote from ser260 was able to recognize and therefore inhibit the formation of a VDR/RXR complex on the 32P-labeled VDRE (Figure (Figure2b).2b). Phosphorylation of ser260 occurs at a critical site close to regions of potential coactivator interaction with the RXR (30, 31). Taken together, these results indicate that a conformational change within the LBD of hRXRα probably occurs following phosphorylation of ser260.

Indeed, several adaptor proteins that can act as coactivators for nuclear receptors have been identified recently (32), including the coactivator SRC-1 (steroid receptor coactivator-1), which can interact with the LBD of steroid receptors to increase ligand-dependent transcriptional activation (33). We cannot exclude the possibility that phosphorylation of ser260 of hRXRα may disrupt the interaction of this heterodimeric partner with SRC-1 or other coactivators and thus attenuate ligand-dependent transactivation. Irrespective of the exact consequences of RXR phosphorylation on RXR conformation, our study has identified a new target of ras activation that may play a critical role in malignant transformation.


We are grateful to M. Sebag, K. Meerovitch, K. LiChong, H.R. Woods, and R. Lin for technical assistance, and to J.S. Rhim for valuable advice and the generation of ras-transformed cells. This work was supported by operating grants to R. Kremer (MT-10839) and J.H. White (MT-11704) from the Medical Research Council of Canada. C. Solomon is the holder of a Blidner and Krupp Families’ studentship from the Royal Victoria Hospital Research Institute. J.H. White is a chercheur-boursier of the Fonds de Recherche en Santé du Québec.


1. McClay EF, Albright KD, Jones JA, Christen RD, Howell SB. Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines. Br J Cancer. 1994;70:449–452. [PMC free article] [PubMed]
2. Zachos G, Spandidos GA. Expression of ras proto-oncogenes: regulation and implications in the development of human tumors. Crit Rev Oncol Hematol. 1997;26:65–75. [PubMed]
3. Davis RJ. The mitogen-activated protein kinase signal transduction pathway. J Biol Chem. 1993;268:14553–14556. [PubMed]
4. Weigel, N.L. 1994. Receptor phosphorylation in molecular biology intelligence unit. In Mechanism of steroid hormone regulation of gene transcription. M-J. Tsai, editor. R.G. Landes Co. Austin, Texas. 93–110.
5. Haussler MR, et al. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res. 1998;13:325–349. [PubMed]
6. Zhou JY, et al. 1,25-dihydroxy-16-ene-23-yne-vitamin D3 prolongs survival time of leukemic mice. Proc Natl Acad Sci USA. 1990;87:3929–3932. [PubMed]
7. Buras RR, et al. Vitamin D receptors in breast cancer cells. Breast Cancer Res Treat. 1994;31:191–202. [PubMed]
8. Yabushita H, Hirata M, Noguchi M, Nakanishi M. Vitamin D receptor in endometrial carcinoma and the differentiation-inducing effect of 1,25-dihydroxyvitamin D3 on endometrial carcinoma cell lines. J Obstet Gynaecol Res. 1996;22:529–539. [PubMed]
9. Kornfehl J, Formanek M, Temmel A, Knerer B, Willheim M. Antiproliferative effects of the biologically active metabolite of vitamin D3 on head and neck squamous cell carcinoma cell lines. Eur Arch Otorhinolaryngol. 1996;253:341–344. [PubMed]
10. Higashimoto Y, et al. 1-alpha,25-dihydroxyvitamin D3 and all-trans retinoic acid inhibit the growth of a lung cancer cell line. Anticancer Res. 1996;16:2653–2659. [PubMed]
11. Hedlund TE, Moffat KA, Miller GJ. Vitamin D receptor expression is required for growth modulation by 1-alpha, 25-dihydroxyvitamin D3 in the human prostatic carcinoma cell line ALVA-31. J Steroid Biochem Mol Biol. 1996;58:277–288. [PubMed]
12. Botling J, et al. Vitamin D3- and retinoic acid-induced monocytic differentiation: interactions between the endogenous vitamin D3 receptor, retinoic acid receptors, and retinoid X receptors in U-937 cells. Cell Growth Differ. 1996;7:1239–1249. [PubMed]
13. Sebag M, Henderson J, Rhim J, Kremer R. Relative resistance to 1,25-dihydroxyvitamin D3 in a keratinocyte model of tumor progression. J Biol Chem. 1992;267:12162–12167. [PubMed]
14. Zugmaier G, et al. Growth inhibitory effects of vitamin D analogues and retinoids on human pancreatic cancer cells. Br J Cancer. 1996;73:1341–1346. [PMC free article] [PubMed]
15. Narvaez CJ, Vanweelden K, Byrne I, Welsh J. Characterization of a vitamin D3-resistant MCF-7 cell line. Endocrinology. 1996;137:400–409. [PubMed]
16. Dürst M, Gallahan D, Jay G, Rhim JS. Glucocorticoid-enhanced neoplastic transformation of human keratinocytes by human papilloma virus type 16 and an activated ras oncogene. Virology. 1989;173:767–771. [PubMed]
17. Solomon C, Sebag M, White JH, Rhim J, Kremer R. Disruption of vitamin D receptor-retinoid X receptor heterodimer formation following ras transformation of human keratinocytes. J Biol Chem. 1998;273:17573–17578. [PubMed]
18. Mangelsdorf DJ, Evans RM. The RXR heterodimers and orphan receptors. Cell. 1995;83:841–850. [PubMed]
19. Dürst M, Dzarlieva-Petrusevska RT, Boukamp P, Fusenig NE, Gissman L. Molecular and cytogenetic analysis of immortalized human primary keratinocytes obtained after transfection with human papilloma virus type 16 DNA. Oncogene. 1987;1:251–256. [PubMed]
20. Ferrara J, McCuaig KA, Hendy GN, Uskokovic M, White JH. Highly potent transcriptional activation by 16-ene derivatives of 1,25-dihydroxyvitamin D3. J Biol Chem. 1994;269:2971–2981. [PubMed]
21. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR. A synthetic inhibitor of the mitogen activated protein kinase cascade. Proc Natl Acad Sci USA. 1995;92:7686–7689. [PubMed]
22. Banville D, Boie Y. Retroviral long terminal repeat is the promoter of the gene encoding the tumor-associated calcium-binding protein oncomodulin in the rat. J Mol Biol. 1990;207:481. [PubMed]
23. Koszewski N, Reinhardt T, Horst R. Vitamin D receptor interactions with the murine osteopontin response element. J Steroid Biochem. 1996;59:377–388. [PubMed]
24. Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR. Site directed mutagenesis by overlap extension using the polymerase chain reaction. Gene. 1989;77:51–59. [PubMed]
25. Henderson J, Sebag M, Rhim J, Goltzman D, Kremer R. Dysregulation of parathyroid hormone-like peptide expression and secretion in a keratinocyte model of tumor progression. Cancer Res. 1991;51:6521–6528. [PubMed]
26. Kaiser SM, Sebag M, Rhim JS, Kremer R, Goltzman D. Antisense-mediated inhibition of parathyroid hormone-related peptide production in a keratinocyte cell line impedes differentiation. Mol Endocrinol. 1994;8:139–147. [PubMed]
27. Niles RM. Use of vitamins A and D in chemoprevention and therapy of cancer: control of nuclear receptor expression and function. Adv Exp Med Biol. 1995;375:1–15. [PubMed]
28. Kliewer SA, et al. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell. 1995;83:813–819. [PubMed]
29. Sarraf P, et al. Differentiation and reversal of malignant changes in colon cancer through PPARγ Nat Med. 1998;4:1046–1052. [PubMed]
30. Westin S, et al. Interactions controlling the assembly of nuclear-receptor heterodimers and co-activators. Nature. 1998;395:199–202. [PubMed]
31. Henttu PM, Kalkoven E, Parker MG. AF-2 activity and recruitment of steroid receptor coactivator 1 to the estrogen receptor depend on a lysine residue conserved in nuclear receptors. Mol Cell Biol. 1997;17:1832–1839. [PMC free article] [PubMed]
32. Meyer ME, et al. Steroid hormone receptors compete for factors that mediate their enhancer function. Cell. 1989;57:433–442. [PubMed]
33. Nolte RT, et al. Ligand binding and coactivator assembly of the peroxisome proliferator-activated receptor-gamma. Nature. 1998;395:137–143. [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation